Estrogen is produced and metabolized in multiple placesincluding fat tissue
Thus, people with hepatic impairment treated with tirzepatide may not require dose adjustments
Mohammadi H, Dehghan SF, Moradi N, et al
The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, randomly assigned 751 adults with obesity to either tirzepatide or semaglutide for 72 weeks.[1] The results were clear: Average weight loss with tirzepatide: 20.2% Average weight loss with semaglutide: 13.7% Tirzepatide patients were also more likely to hit major milestones 10%, 15%, 20%, and even 25% body weight loss
The smartest approach is making sure your body is protected while you use it and supported long after the weight loss phase is over.
While it differs from once-weekly injections like those used for semaglutide drugs, PhenQ offers a natural semaglutide alternative without injections or the potential abdominal discomfort associated with glucagon-like peptide-1 receptor agonists
